Higher incidence of dermatological immune-related adverse events in cancer patients treated with immune checkpoint inhibitors vs. other treatments: a TriNetX research network study

Authors

Rahib K. Islam, LSU Health Sciences Center - New OrleansFollow
Ryan Chan, New York Medical College
Andrew Gross, Tulane University School of Medicine
Hassan Malik, LSU Health Sciences Center - New OrleansFollow
Humza Pirzadah, LSU Health Sciences Center - New OrleansFollow
Ahmed Abdelmaksoud, Tulane University School of Medicine
Christopher Haas, LSU Health Sciences Center - New OrleansFollow
Manal Fawzy, Northern Border University
Eman Toraih, Tulane University School of Medicine
Shari R. Lipner, Weill Cornell Medicine

Document Type

Letter to the Editor

Publication Date

5-30-2025

Publication Title

Archives of Dermatological Research

PubMed ID

40445399

Volume

317

Issue

1

Recommended Citation

Islam, Rahib K.; Chan, Ryan; Gross, Andrew; Malik, Hassan; Pirzadah, Humza; Abdelmaksoud, Ahmed; Haas, Christopher; Fawzy, Manal; Toraih, Eman; and Lipner, Shari R., "Higher incidence of dermatological immune-related adverse events in cancer patients treated with immune checkpoint inhibitors vs. other treatments: a TriNetX research network study" (2025). School of Medicine Faculty Publications. 3850.
https://digitalscholar.lsuhsc.edu/som_facpubs/3850
10.1007/s00403-025-04288-7